Purple Biotech's IM1240 Tri-specific Antibody Shows Expanded Therapeutic Window in Toxicology Study

summarizeSummary

Purple Biotech announced positive preclinical toxicology results for its lead CAPTN-3 platform candidate, IM1240, demonstrating an expanded therapeutic window and improved safety profile.

check_boxKey Events

• Positive Toxicology Results

  IM1240, a CAPTN-3 tri-specific antibody, successfully completed a non-human primate toxicology study.

• Expanded Therapeutic Window Demonstrated

  The study showed IM1240 could be dosed up to 300-fold higher than a non-capped comparator with significantly reduced immune-related toxicity and minimal cytokine release.

• Favorable Pharmacokinetic Profile

  IM1240 exhibited increased systemic exposure and a prolonged circulating half-life.

• Advancing Towards Clinical Trials

  The company plans regulatory submission for first-in-human clinical trials for IM1240 in the second half of 2026.

auto_awesomeAnalysis

The successful completion of a non-human primate toxicology study for IM1240 is a significant de-risking event for Purple Biotech's lead tri-specific antibody program. The data showing IM1240 can be dosed 300-fold higher than a comparator with minimal immune-related toxicity, including reduced cytokine release, addresses a key challenge in T-cell engager therapies. This expanded therapeutic window and favorable pharmacokinetic profile provide a strong foundation for advancing IM1240 towards first-in-human clinical trials, with regulatory submission anticipated in the second half of 2026. This milestone enhances the program's potential and provides a clear path forward for the company's CAPTN-3 platform.